Marshall and Dunaif Page 9
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model
assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin
concentrations in man. Diabetologia. 1985; 28:412–9. [PubMed: 3899825]
NIH-PA Author Manuscript
28. Legro RS, Dunaif A. Fasting glucose to insulin ratio or product of glucose and insulin? J Clin
Endocrinol Metab. 1999; 84:383.
29. Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by
simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and
prevention. J Clin Endocrinol Metab. 2002; 87:144–7. [PubMed: 11788638]
30. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and
management of the metabolic syndrome: An American Heart Association/National Heart, Lung,
and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–52. [PubMed: 16157765]
31. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical
management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and
adjustment of therapy: a consensus statement of the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203. [PubMed:
18945920]
32. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting
glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30:753–9.
[PubMed: 17327355]
33. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone,
pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;
3:CD003053. [PubMed: 12917943]
NIH-PA Author Manuscript
34. Singh S, Loke YK, Furberg CD. Long-term Risk of Cardiovascular Events With Rosiglitazone.
JAMA: The Journal of the American Medical Association. 2007; 298:1189–95. [PubMed:
17848653]
35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in
Patients With Type 2 Diabetes Mellitus. JAMA: The Journal of the American Medical
Association. 2007; 298:1180–8. [PubMed: 17848652]
36. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, et al. Risk of Bladder
Cancer Among Diabetic Patients Treated With Pioglitazone. Diabetes Care. 2011; 34:916–22.
[PubMed: 21447663]
37. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight
loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374:1677–86. [PubMed:
19878986]
38. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and
Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2008; 93:1105–20. [PubMed: 18252793]
39. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to
accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary
syndrome. J Clin Endocrinol Metab. 2004; 89:1273–6. [PubMed: 15001622]
NIH-PA Author Manuscript
Fertil Steril. Author manuscript; available in PMC 2013 January 1.